Risk Stratification of Patients With MF

Aaron Gerds, MD, MS, explains that unlike solid tumors, blood cancers are systemic, so risk stratification models like DIPSS that use readily available data on blood counts and physical exam are more useful prognostically; however, mutation analysis is becoming increasingly important for determining prognosis and targeting therapies.